NUVB
Nuvation Bio Inc.
Price Chart
Latest Quote
$5.96
+0.20 (+3.39%)
Current Price
| Previous Close | $5.76 |
| Open | $5.71 |
| Day High | $6.03 |
| Day Low | $5.66 |
| Volume | 1,727,150 |
Stock Information
| Shares Outstanding | 347.20M |
| Total Debt | $216.98M |
| Cash Equivalents | $533.73M |
| Revenue | $143.05M |
| Net Income | $-145.99M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.10B |
| EPS (TTM) | $-0.43 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.69B |
| Sales | $143.05M |
| Income | $-145.99M |
| Book/sh | $0.92 |
| Cash/sh | $1.54 |
| Employees | 307 |
Financial Ratios
| Quick Ratio | 7.04 |
| Current Ratio | 7.44 |
| Debt/Eq | 67.90 |
Returns & Margins
| ROA | -17.02% |
| ROE | -39.51% |
| Gross Margin | 90.78% |
| Operating Margin | 4.66% |
| Profit Margin | -102.06% |
Ownership
| Insider Ownership | 18.59% |
| Institutional Ownership | 64.86% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -100.50 |
| P/S | 14.68 |
| P/B | 6.56 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $12.33 |
Technical Indicators
| SMA20 | $5.02 |
| SMA50 | $4.84 |
| SMA200 | $5.35 |
| RSI | 69.02 |
| ATR | 0.4085 |
| Shares Float | 254.66M |
| Short Float | 25.52% |
| Short Ratio | 11.97 |
| Volatility | 1.56 |
| Rel Volume | 0.94 |
Performance History
| Week | +17.32% |
| Month | +25.89% |
| Quarter | +38.62% |
| 6 Months | -32.93% |
| YTD | -29.72% |
| Year | +206.09% |
| 3 Years | +242.61% |
| 5 Years | -45.87% |
| 10 Years | -37.84% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $6.03 | 4,195,169 |
| 2026-06-22 | $5.76 | 4,159,300 |
| 2026-06-18 | $5.56 | 4,730,300 |
| 2026-06-17 | $5.33 | 5,416,900 |
| 2026-06-16 | $5.12 | 3,625,200 |
| 2026-06-15 | $5.14 | 4,183,900 |
| 2026-06-12 | $4.92 | 5,250,500 |
| 2026-06-11 | $4.76 | 3,457,200 |
| 2026-06-10 | $4.58 | 6,614,500 |
| 2026-06-09 | $4.93 | 9,714,600 |
| 2026-06-08 | $4.80 | 2,964,900 |
| 2026-06-05 | $4.82 | 3,476,100 |
| 2026-06-04 | $5.17 | 6,720,400 |
| 2026-06-03 | $4.72 | 3,230,600 |
| 2026-06-02 | $4.90 | 4,300,900 |
| 2026-06-01 | $4.96 | 5,960,600 |
| 2026-05-29 | $4.78 | 4,201,600 |
| 2026-05-28 | $4.75 | 1,436,100 |
| 2026-05-27 | $4.74 | 3,017,900 |
| 2026-05-26 | $4.69 | 2,718,200 |
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
đ° Latest News
Veteran Pharma VC Insider Buys 25,000 Nuvation Bio Shares as New Drug Gains Momentum
Motley Fool âĸ 2026-06-17T16:21:53Z
Hereâs What the Acquisition of Nuvalent Means for Nuvation Bio (NUVB)
Insider Monkey âĸ 2026-06-16T18:45:52Z
Spotlight On Promising Penny Stocks For June 2026
Simply Wall St. âĸ 2026-06-10T12:05:17Z
Nuvation Bio Sharpens IBTROZI Focus With Thermo Fisher And FDA Steps
Simply Wall St. âĸ 2026-05-18T11:07:20Z
Thermo Fisher Deepens Oncology Role With Ibtrozi Manufacturing Milestone
Simply Wall St. âĸ 2026-05-18T04:29:50Z
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
Motley Fool âĸ 2026-05-15T23:02:41Z
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
Motley Fool âĸ 2026-05-15T22:56:41Z
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
Motley Fool âĸ 2026-05-15T22:50:53Z
Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying.
Barrons.com âĸ 2026-05-15T21:59:00Z
Is Nuvation Bio (NUVB) the Best Penny Stock to Buy Before It Explodes?
Insider Monkey âĸ 2026-05-13T06:21:36Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $9,298,000 | $7,078,000 | $0 | - |
| Cost Of Revenue | $9,298,000 | $7,078,000 | $0 | - |
| Total Revenue | $62,902,000 | $7,873,000 | $0 | $0 |
| Operating Revenue | $62,902,000 | $7,873,000 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $13,682,000 | $341,000 | $0 | - |
| Total Expenses | $275,966,000 | $175,430,000 | $99,822,000 | $119,734,000 |
| Other Income Expense | $689,000 | $-427,103,000 | $-591,000 | $8,087,000 |
| Other Non Operating Income Expenses | $1,529,000 | $-1,085,000 | $-949,000 | $-872,000 |
| Net Non Operating Interest Income Expense | $7,748,000 | $26,721,000 | $24,611,000 | $7,448,000 |
| Interest Expense Non Operating | $13,682,000 | $341,000 | $0 | - |
| Operating Expense | $266,668,000 | $168,352,000 | $99,822,000 | $119,734,000 |
| General And Administrative Expense | - | - | $28,533,000 | $31,919,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-204,627,000 | $-567,939,000 | $-75,802,000 | $-104,199,000 |
| Net Interest Income | $7,748,000 | $26,721,000 | $24,611,000 | $7,448,000 |
| Interest Income | $21,430,000 | $27,062,000 | $24,611,000 | $7,448,000 |
| Normalized Income | $-203,787,000 | $-141,921,000 | $-76,160,000 | $-113,158,000 |
| Net Income From Continuing And Discontinued Operation | $-204,627,000 | $-567,939,000 | $-75,802,000 | $-104,199,000 |
| Total Operating Income As Reported | $-213,064,000 | $-592,627,000 | $-99,822,000 | $-119,734,000 |
| Net Income Common Stockholders | $-204,627,000 | $-567,939,000 | $-75,802,000 | $-104,199,000 |
| Net Income | $-204,627,000 | $-567,939,000 | $-75,802,000 | $-104,199,000 |
| Net Income Including Noncontrolling Interests | $-204,627,000 | $-567,939,000 | $-75,802,000 | $-104,199,000 |
| Net Income Continuous Operations | $-204,627,000 | $-567,939,000 | $-75,802,000 | $-104,199,000 |
| Pretax Income | $-204,627,000 | $-567,939,000 | $-75,802,000 | $-104,199,000 |
| Special Income Charges | $-33,000 | $-425,070,000 | $0 | - |
| Interest Income Non Operating | $21,430,000 | $27,062,000 | $24,611,000 | $7,448,000 |
| Operating Income | $-213,064,000 | $-167,557,000 | $-99,822,000 | $-119,734,000 |
| Gross Profit | $53,604,000 | $795,000 | $0 | - |
| Per Share | ||||
| Diluted EPS | $-0.60 | $-2.11 | $-0.35 | $-0.48 |
| Basic EPS | $-0.60 | $-2.11 | $-0.35 | $-0.48 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-188,366,000 | $-140,897,000 | $-75,938,000 | $-128,494,000 |
| Total Unusual Items | $-840,000 | $-426,018,000 | $358,000 | $8,959,000 |
| Total Unusual Items Excluding Goodwill | $-840,000 | $-426,018,000 | $358,000 | $8,959,000 |
| Reconciled Depreciation | $1,739,000 | $683,000 | $222,000 | $199,000 |
| EBITDA (Bullshit earnings) | $-189,206,000 | $-566,915,000 | $-75,580,000 | $-119,535,000 |
| EBIT | $-190,945,000 | $-567,598,000 | $-75,802,000 | $-119,734,000 |
| Diluted Average Shares | $341,541,000 | $268,772,000 | $218,880,000 | $216,721,000 |
| Basic Average Shares | $341,541,000 | $268,772,000 | $218,880,000 | $216,721,000 |
| Diluted NI Availto Com Stockholders | $-204,627,000 | $-567,939,000 | $-75,802,000 | $-104,199,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Gain On Sale Of Ppe | $-33,000 | $0 | - | - |
| Gain On Sale Of Security | $-807,000 | $-948,000 | $358,000 | $8,959,000 |
| Research And Development | $115,106,000 | $99,119,000 | $71,289,000 | $87,815,000 |
| Selling General And Administration | $151,562,000 | $69,233,000 | $28,533,000 | $31,919,000 |
| Other Special Charges | - | $425,070,000 | - | - |
| Other Gand A | - | - | $28,533,000 | $31,919,000 |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $294,502,000 | $459,166,000 | $605,122,000 | $655,076,000 |
| Total Assets | $594,822,000 | $540,626,000 | $621,484,000 | $672,141,000 |
| Total Non Current Assets | $23,303,000 | $14,371,000 | $5,050,000 | $4,823,000 |
| Other Non Current Assets | $7,607,000 | $6,761,000 | $587,000 | - |
| Goodwill And Other Intangible Assets | $11,214,000 | $4,622,000 | $0 | - |
| Current Assets | $571,519,000 | $526,255,000 | $616,434,000 | $667,318,000 |
| Other Current Assets | $11,536,000 | $7,271,000 | $1,519,000 | $3,819,000 |
| Inventory | $11,411,000 | $0 | - | - |
| Receivables | $19,361,000 | $16,292,000 | $3,702,000 | $2,485,000 |
| Accrued Interest Receivable | $3,285,000 | $3,570,000 | $3,702,000 | $2,485,000 |
| Accounts Receivable | $16,076,000 | $12,722,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $529,211,000 | $502,692,000 | $611,213,000 | $661,014,000 |
| Cash And Cash Equivalents | $164,086,000 | $35,723,000 | $42,649,000 | $101,099,000 |
| Non Current Prepaid Assets | - | $145,000 | $141,000 | $138,000 |
| Current Deferred Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $57,355,000 | $8,915,000 | $4,007,000 | $4,260,000 |
| Long Term Debt And Capital Lease Obligation | $49,751,000 | $969,000 | $2,035,000 | $3,054,000 |
| Long Term Debt | $47,208,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $7,604,000 | $7,946,000 | $1,972,000 | $1,206,000 |
| Current Debt | $5,724,000 | $6,283,000 | - | - |
| Other Current Borrowings | $5,724,000 | $6,283,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $289,106,000 | $76,838,000 | $16,362,000 | $17,065,000 |
| Total Non Current Liabilities Net Minority Interest | $206,875,000 | $18,594,000 | $2,388,000 | $3,904,000 |
| Other Non Current Liabilities | $145,819,000 | - | - | - |
| Derivative Product Liabilities | $0 | $2,053,000 | $353,000 | $850,000 |
| Non Current Deferred Liabilities | $11,305,000 | $15,572,000 | $0 | - |
| Current Liabilities | $82,231,000 | $58,244,000 | $13,974,000 | $13,161,000 |
| Other Current Liabilities | $12,450,000 | - | - | - |
| Current Deferred Liabilities | $7,515,000 | $11,117,000 | $0 | - |
| Payables And Accrued Expenses | $34,661,000 | $24,363,000 | $7,653,000 | $7,968,000 |
| Payables | $9,765,000 | $7,027,000 | $2,353,000 | $2,251,000 |
| Total Tax Payable | $286,000 | $679,000 | $144,000 | $112,000 |
| Accounts Payable | $9,479,000 | $6,348,000 | $2,209,000 | $2,139,000 |
| Equity | ||||
| Common Stock Equity | $305,716,000 | $463,788,000 | $605,122,000 | $655,076,000 |
| Total Equity Gross Minority Interest | $305,716,000 | $463,788,000 | $605,122,000 | $655,076,000 |
| Stockholders Equity | $305,716,000 | $463,788,000 | $605,122,000 | $655,076,000 |
| Gains Losses Not Affecting Retained Earnings | $-187,000 | $573,000 | $181,000 | $-5,526,000 |
| Other Equity Adjustments | $-187,000 | $573,000 | $181,000 | $-5,526,000 |
| Retained Earnings | $-1,115,370,000 | $-910,743,000 | $-342,804,000 | $-267,002,000 |
| Other | ||||
| Ordinary Shares Number | $346,503,675 | $337,837,872 | $219,046,219 | $218,632,699 |
| Share Issued | $346,503,675 | $337,837,872 | $219,046,219 | $218,632,699 |
| Tangible Book Value | $294,502,000 | $459,166,000 | $605,122,000 | $655,076,000 |
| Invested Capital | $358,648,000 | $470,071,000 | $605,122,000 | $655,076,000 |
| Working Capital | $489,288,000 | $468,011,000 | $602,460,000 | $654,157,000 |
| Capital Lease Obligations | $4,423,000 | $2,632,000 | $4,007,000 | $4,260,000 |
| Total Capitalization | $352,924,000 | $463,788,000 | $605,122,000 | $655,076,000 |
| Capital Stock | $1,421,273,000 | $1,373,958,000 | $947,745,000 | $927,604,000 |
| Common Stock | $1,421,273,000 | $1,373,958,000 | $947,745,000 | $927,604,000 |
| Non Current Deferred Revenue | $11,305,000 | $15,572,000 | $0 | - |
| Long Term Capital Lease Obligation | $2,543,000 | $969,000 | $2,035,000 | $3,054,000 |
| Current Deferred Revenue | $7,515,000 | $11,117,000 | $0 | - |
| Current Capital Lease Obligation | $1,880,000 | $1,663,000 | $1,972,000 | $1,206,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $20,001,000 | $14,818,000 | $4,349,000 | $3,987,000 |
| Current Accrued Expenses | $24,896,000 | $17,336,000 | $5,300,000 | $5,717,000 |
| Net PPE | $4,482,000 | $2,988,000 | $4,322,000 | $4,685,000 |
| Accumulated Depreciation | $-1,184,000 | $-874,000 | $-666,000 | $-458,000 |
| Gross PPE | $5,666,000 | $3,862,000 | $4,988,000 | $5,143,000 |
| Leases | $536,000 | $353,000 | $342,000 | $316,000 |
| Construction In Progress | $28,000 | $0 | - | - |
| Other Properties | $3,918,000 | $2,402,000 | $3,605,000 | $3,791,000 |
| Machinery Furniture Equipment | $1,184,000 | $1,107,000 | $1,041,000 | $1,036,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $365,125,000 | $466,969,000 | $568,564,000 | $559,915,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-181,781,000 | $-130,575,000 | $-68,068,000 | $-96,478,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-173,427,000 | $-130,413,000 | $-67,999,000 | $-96,108,000 |
| Cash Flow From Continuing Operating Activities | $-173,427,000 | $-130,413,000 | $-67,999,000 | $-96,108,000 |
| Operating Gains Losses | $-245,000 | $1,177,000 | $-348,000 | $-8,909,000 |
| Investing Activities | ||||
| Capital Expenditure | $-8,354,000 | $-162,000 | $-69,000 | $-370,000 |
| Investing Cash Flow | $99,520,000 | $122,703,000 | $8,921,000 | $63,457,000 |
| Cash Flow From Continuing Investing Activities | $99,520,000 | $122,703,000 | $8,921,000 | $63,457,000 |
| Financing Activities | ||||
| Financing Cash Flow | $202,535,000 | $331,000 | $628,000 | $1,327,000 |
| Cash Flow From Continuing Financing Activities | $202,535,000 | $331,000 | $628,000 | $1,327,000 |
| Net Other Financing Charges | $142,911,000 | - | - | - |
| Issuance Of Capital Stock | - | - | - | - |
| Net Common Stock Issuance | - | - | - | - |
| Common Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-11,899,000 | $-17,163,000 | $0 | - |
| Issuance Of Debt | $60,102,000 | $12,609,000 | $0 | - |
| Interest Paid Supplemental Data | $2,882,000 | $341,000 | $0 | - |
| Income Tax Paid Supplemental Data | $197,000 | $373,000 | $0 | - |
| End Cash Position | $164,086,000 | $35,723,000 | $42,649,000 | $101,099,000 |
| Beginning Cash Position | $35,723,000 | $42,649,000 | $101,099,000 | $132,423,000 |
| Effect Of Exchange Rate Changes | $-265,000 | $453,000 | $0 | - |
| Changes In Cash | $128,628,000 | $-7,379,000 | $-58,450,000 | $-31,324,000 |
| Proceeds From Stock Option Exercised | $11,421,000 | $4,885,000 | $628,000 | $1,327,000 |
| Net Issuance Payments Of Debt | $48,203,000 | $-4,554,000 | $0 | - |
| Net Short Term Debt Issuance | $48,203,000 | $-4,554,000 | $0 | - |
| Short Term Debt Payments | $-11,899,000 | $-17,163,000 | $0 | - |
| Short Term Debt Issuance | $60,102,000 | $12,609,000 | $0 | - |
| Net Investment Purchase And Sale | $107,874,000 | $110,437,000 | $8,976,000 | $63,814,000 |
| Sale Of Investment | $462,290,000 | $450,082,000 | $712,349,000 | $584,121,000 |
| Purchase Of Investment | $-354,416,000 | $-339,645,000 | $-703,373,000 | $-520,307,000 |
| Net Business Purchase And Sale | $0 | $12,428,000 | $0 | - |
| Sale Of Business | $0 | $19,862,000 | $0 | - |
| Purchase Of Business | $0 | $-7,434,000 | $0 | - |
| Net Intangibles Purchase And Sale | $-8,000,000 | $0 | - | - |
| Purchase Of Intangibles | $-8,000,000 | $0 | - | - |
| Net PPE Purchase And Sale | $-354,000 | $-162,000 | $-55,000 | $-357,000 |
| Purchase Of PPE | $-354,000 | $-162,000 | $-69,000 | $-370,000 |
| Change In Working Capital | $-11,979,000 | $-12,507,000 | $540,000 | $-3,447,000 |
| Change In Other Working Capital | $-7,869,000 | $3,942,000 | - | $283,000 |
| Change In Other Current Assets | $-846,000 | $-6,033,000 | $-587,000 | $0 |
| Change In Payables And Accrued Expense | $15,481,000 | $5,184,000 | $47,000 | $-4,107,000 |
| Change In Accrued Expense | $12,350,000 | $6,838,000 | $-23,000 | $-2,321,000 |
| Change In Payable | $3,131,000 | $-1,654,000 | $70,000 | $-1,786,000 |
| Change In Account Payable | $3,131,000 | $-1,654,000 | $70,000 | $-1,786,000 |
| Change In Prepaid Assets | $-4,265,000 | $-3,010,000 | $2,297,000 | $106,000 |
| Change In Inventory | $-11,411,000 | $0 | - | - |
| Change In Receivables | $-3,069,000 | $-12,590,000 | $-1,217,000 | $554,000 |
| Changes In Account Receivables | $-3,354,000 | $-12,722,000 | $0 | - |
| Other Non Cash Items | $11,075,000 | $424,898,000 | $-67,000 | $285,000 |
| Stock Based Compensation | $35,894,000 | $32,275,000 | $19,513,000 | $16,292,000 |
| Amortization Of Securities | $-5,284,000 | $-9,000,000 | $-12,057,000 | $3,671,000 |
| Depreciation Amortization Depletion | $1,739,000 | $683,000 | $222,000 | $199,000 |
| Depreciation And Amortization | $1,739,000 | $683,000 | $222,000 | $199,000 |
| Gain Loss On Investment Securities | $807,000 | $948,000 | $-358,000 | $-8,959,000 |
| Net Foreign Currency Exchange Gain Loss | $-1,085,000 | $0 | - | - |
| Gain Loss On Sale Of PPE | $33,000 | $229,000 | $10,000 | $50,000 |
| Net Income From Continuing Operations | $-204,627,000 | $-567,939,000 | $-75,802,000 | $-104,199,000 |
| Sale Of PPE | - | $0 | $14,000 | $13,000 |
Fetched: 2026-06-22